Comparison of structure, strength and cytocompatibility of a fibrin matrix supplemented either with tranexamic acid or aprotinin

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 82, Issue 1, 2007, Pages 109-114

  Furst, Walter ^a   Banerjee, Asmita ^a   Redl, Heinz ^a  

^a FEDERAL RESEARCH AND TRAINING CENTRE FOR FORESTS   (Austria)

Author keywords

Biocompatibility soft tissue; Fibrin; Hemostasis; Mechanical properties; Wound healing

Indexed keywords

BIOMATERIALS; PHYSIOLOGICAL MODELS; TENSILE STRENGTH; TISSUE; TISSUE ENGINEERING;

FIBRIN; HEMOSTASIS; WOUND HEALING;

PROTEINS;

APROTININ; FIBRIN GLUE; TRANEXAMIC ACID;

ADHESION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; BLEEDING; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; FIBROBLAST; HEMOSTASIS; HUMAN; HUMAN CELL; LUNG RESECTION; NONHUMAN; RABBIT; SCANNING ELECTRON MICROSCOPY; SOFT TISSUE INFECTION; TENSILE STRENGTH; WOUND HEALING;

ANIMALS; ANTIFIBRINOLYTIC AGENTS; APROTININ; FIBRIN; FIBRIN TISSUE ADHESIVE; LUNG; MATERIALS TESTING; MICROSCOPY, ELECTRON, SCANNING; RABBITS; TENSILE STRENGTH; TRANEXAMIC ACID;

EID: 34347357469     PISSN: 15524973     EISSN: 15524981     Source Type: Journal    
DOI: 10.1002/jbm.b.30711     Document Type: Article

References (22)

1. Redl H. History of tissue adhesives. In: Saltz R, Toriumi D, editors. Tissue Glues in Cosmetic Surgery. St. Louis: Quality Medical Publishing; 2004. pp 3-27.
2. Gil F, Garcia-Aguado R, Barcia JA, Guijarro E, Hostalet F, Tommasi-Rosso M, Grau F. The effect of fibrin glue patch in an in vitro model of postdural puncture leakage. Anesth Analg 1998;87:1125-1128.
3. Peng H, Sahni A, Fay P, Bellum S, Prudovsky I, Maciag T, Francis CW. Identification of a binding site on human FGF-2 for fibrinogen. Blood 2004;103:2114-2120.
4. Sahni A, Francis CW. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood 2000;96:3772-3778.
5. Tonnesen MG, Feng X, Clark RA. Angiogenesis in wound healing. J Investig Dermatol Symp Proc 2000;5:40-46.
6. Sahni A, Guo M, Sahni SK, Francis CW. Interleukin-1β but not IL-1α binds to fibrinogen and fibrin and has enhanced activity in the bound form. Blood 2004;104:409-414.
7. Walsh PN, Ahmad SS. Proteases in blood clotting. Essays Biochem 2002;38:95-111.
8. Imamura T, Kaneda H, Nakamura S. New functions of neutrophils in the arthus reaction: Expression of tissue factor, the clotting initiator, and fibrinolysis by elastase. Lab Invest 2002; 82:1287-1295.
9. Moir E, Robbie LA, Bennett B, Booth NA. Polymorphonuclear leucocytes have two opposing roles in fibrinolysis. Thromb Haemost 2002;87:1006-1010.
10. Pipan CM, Glasheen WP, Matthew TL, Gonias SL, Hwang LJ, Jane JA, Spotnitz WD. Effects of antifibrinolytic agents on the life span of fibrin sealant. J Surg Res 1992;53:402-407.
11. Levy JH. Efficacy and safety of aprotinin in cardiac surgery. Orthopedics 2004;27:s659-s662.
12. Dunn CJ, Goa KL. Tranexamic acid: A review of its use in surgery and other indications. Drugs 1999;57:1005-1032.
13. Suenson E, Lutzen O, Thorsen S. Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis. Eur J Biochem 1984;140:513-522.
14. Markwardt F. Synthetic inhibitors of fibrinolysis. In: Markwardt F, editor. Fibrinolytics and Antifibrinolytics. Berlin: Springer Verlag; 1978. pp 511-577.
15. Schlag MG, Hopf R, Redl H. Convulsive seizures following subdural application of fibrin sealant containing tranexamic acid in a rat model. Neurosurgery 2000;47:1463-1467.
16. Furtmuller R, Schlag MG, Berger M, Hopf R, Huck S, Sieghart W, Redl H. Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a γ-aminobutyric acid(A) receptor antagonistic effect. J Pharmacol Exp Ther 2002;301:168-173.
17. Ferry JD, Morrison PR. Preparation and properties of serum and plasma proteins. VIII. The conversion of human fibrinogen to fibrin under various conditions. J Am Chem Soc 1947; 69:388-400.
18. - regulates the structure of the fibrin clot. Biophys J 1998;75:1973-1979.
19. Glidden PF, Malaska C, Herring SW. Thromboelastograph assay for measuring the mechanical strength of fibrin sealant clots. Clin Appl Thromb Hemost 2000;6:226-233.
20. Shen L, Lorand L. Contribution of fibrin stabilization to clot strength. Supplementation of factor XIII-deficient plasma with the purified zymogen. J Clin Invest 1983;71:1336-1341.
21. Dowd NP, Karski JM, Cheng DC, Carroll JA, Lin Y, James RL, Butterworth J. Pharmacokinetics of tranexamic acid during cardiopulmonary bypass. Anesthesiology 2002;97:390-399.
22. Cox S, Cole M, Mankarious S, Tawil N. Effect of tranexamic acid incorporated in fibrin sealant clots on the cell behavior of neuronal and nonneuronal cells. J Neurosci Res 2003;72: 734-46.